Why the Type Matters
A patient who has been told they have Type 2 diabetes but actually has LADA — an autoimmune form that mimics Type 2 in its early stages — will be managed with the wrong medications for years. Their blood sugar will worsen despite apparently doing everything right. Eventually they'll require insulin, and someone will tell them they "failed" their treatment. In reality, the diagnosis was wrong from the start.
This isn't rare. Studies suggest LADA accounts for 2–12% of adult-onset diabetes cases. Up to 80% of MODY cases are misdiagnosed as Type 1 or Type 2. More than 97% of Type 3c cases are incorrectly coded as Type 2 in clinical records. The consequences aren't minor: wrong diagnosis leads to wrong medication, which leads to poor control, which accelerates complications.
This post walks through each type in enough detail to understand what's happening biologically, what distinguishes it from the others, and — for the variants — what clinical patterns should prompt a second look at the diagnosis.
How Common Is Diabetes, Globally?
Diabetes is one of the fastest-growing health crises in the world. The IDF Diabetes Atlas 11th Edition estimates 589 million people are living with diabetes globally — 11.1% of adults aged 20–79 — with projections reaching 853 million by 2050. An earlier Global Burden of Disease analysis projected even higher figures using different methodology, but the direction is unambiguous in both: this is accelerating.
The regional picture is striking. The highest current prevalence is in the Middle East and North Africa (nearly 20% of adults). Africa has the lowest prevalence today but faces the largest projected relative increase — 142% — by 2050. More than 80% of people with Type 2 diabetes live in low- and middle-income countries, where access to diagnosis and treatment is most limited.
Type 1 Diabetes: The Immune System Turns on the Pancreas
Type 1 diabetes is an autoimmune disease. The body's immune system — which normally identifies and destroys foreign invaders — mistakenly identifies the insulin-producing beta cells in the pancreas as a threat and destroys them. The trigger for this misdirected attack is not fully understood, but it involves a combination of genetic susceptibility (particularly variants in HLA genes that regulate immune recognition) and environmental factors that are still being actively researched, including viral infections and changes in the gut microbiome.
The destruction of beta cells is gradual but ultimately near-complete. Once enough beta cells are gone, the pancreas can no longer produce meaningful amounts of insulin. Without insulin, glucose cannot enter cells — so it accumulates in the bloodstream while tissues are simultaneously starved of fuel. The body responds by breaking down fat for energy, producing acidic byproducts called ketones (ketoacidosis) in the process. Left untreated, this cascade is fatal. Insulin replacement is not optional for Type 1 — it is the difference between life and death.
Type 1 most commonly presents in childhood or young adulthood — hence the older term "juvenile diabetes" — but it can and does occur at any age. The 2026 ADA Standards of Care now explicitly classify all autoimmune beta-cell destruction, regardless of age at onset, under the Type 1 umbrella. Adults who develop autoimmune diabetes are sometimes misdiagnosed with Type 2, particularly if they are not underweight — which is one reason LADA (discussed below) has historically gone unrecognized.
Type 1 diabetes prevalence was estimated at 8.4 million people globally in 2021, projected to rise to 13.5–17.4 million by 2040. In the US, Type 1 accounts for approximately 5–10% of all diabetes cases. The incidence rate has been rising approximately 2–3% per year in high-income countries over the past several decades — a rate too fast to be explained by genetics alone, strongly suggesting environmental contributors. The peak age of diagnosis is 10–14 years, but a significant proportion of new Type 1 diagnoses — possibly the majority — now occur in adults.
The honeymoon period — and why it matters
Shortly after diagnosis and the start of insulin therapy, many people with Type 1 experience a period of dramatically reduced insulin requirements — sometimes approaching zero — that can last weeks to months. This is called the honeymoon period (or partial remission). It occurs because insulin therapy relieves the stress on the remaining beta cells, allowing them to temporarily resume meaningful function.
The honeymoon period ends as the immune attack continues and the residual beta cells are destroyed. Insulin requirements climb back up, permanently. This pattern — initial diagnosis, apparent improvement, then progressive worsening — is important to recognize. In adults, a prolonged honeymoon period that doesn't resolve as expected is one of the clinical clues that LADA may be the correct diagnosis rather than Type 2.
Type 2 Diabetes: Resistance, Then Exhaustion
Type 2 diabetes develops through a two-stage process. The first stage is insulin resistance — the body's cells stop responding normally to insulin's signal to take up glucose. The pancreas compensates by producing more insulin, and blood sugar stays roughly normal for a time. The second stage begins when the pancreas can no longer keep up: beta cells, working overtime to compensate for resistance, begin to fail. As insulin secretion falls, blood glucose rises — and Type 2 diabetes is diagnosed. Progressive beta-cell dysfunction is the key biological feature that separates established Type 2 diabetes from pre-diabetes: pre-diabetes involves insulin resistance, but the beta cells are still compensating adequately.
What drives insulin resistance? The primary culprits are visceral fat (fat stored around the abdominal organs, which releases inflammatory signals that interfere with insulin signaling), physical inactivity, and genetic predisposition. Sleep deprivation, chronic stress, and certain medications also contribute. Type 2 is clinically heterogeneous — its presentation and rate of progression vary considerably between individuals — and it is not simply a matter of eating too much sugar.
Unlike Type 1, Type 2 progresses gradually over years, often with no symptoms in the early stages. Many patients are diagnosed incidentally on routine bloodwork, or not until complications are already present. By the time someone feels unwell from Type 2, significant damage may already have occurred — which is one reason screening matters.
Beta-cell function declines approximately 4–5% per year from the time of Type 2 diagnosis, even with optimal medical management, according to the UK Prospective Diabetes Study (UKPDS). By the time most patients are diagnosed, they have already lost roughly 50% of their beta-cell function. Type 2 accounts for 85–95% of diabetes cases in developed countries and 96% of all diabetes worldwide. This progressive loss is why Type 2 typically requires escalating treatment over time — not because of treatment failure, but because the disease itself advances.
In practice, adults presenting with new-onset diabetes are often initially treated as Type 2 — and that's frequently reasonable. But when blood sugar continues to worsen despite medication and genuine lifestyle effort, or when a patient's weight and habits haven't changed in a way that explains deterioration, that's the signal to dig deeper. The root cause may be something else entirely. Revisiting the diagnosis is not admitting error — it's good medicine.
Type 1 vs. Type 2 at a Glance
These two conditions share a name and a symptom — elevated blood glucose — but they differ in almost every meaningful way. Here's a direct comparison across the features that matter most clinically.
C-peptide is a protein released alongside insulin during its production — measuring it is a reliable way to estimate how much insulin the pancreas is still making. A low or undetectable C-peptide in a patient thought to have Type 2 should prompt reconsideration of the diagnosis. So should positive autoimmune antibodies (particularly GAD65). These tests are underused in clinical practice.
The Variants: Less Common, Frequently Missed
Type 1 and Type 2 together account for the vast majority of diabetes cases, but they are not the whole picture. Several other forms are common enough to warrant understanding — particularly because they are frequently misdiagnosed, and the misdiagnosis has real treatment consequences.
LADA — Latent Autoimmune Diabetes in Adults
2–12% of adult-onset diabetesLADA involves slowly progressive autoimmune beta-cell destruction in adults — the same fundamental process as Type 1, but unfolding over years rather than months. The 2026 ADA Standards note that LADA likely represents a heterogeneous group: some cases are true autoimmune (Type 1) diabetes with slow progression; others may reflect false-positive autoantibody results in people who actually have Type 2. The term LADA remains accepted in clinical practice because it draws attention to the possibility of autoimmune destruction in adults who would otherwise be assumed to have Type 2.
Because patients are adults, often not dramatically underweight, and don't present with rapid-onset symptoms, they are almost always initially diagnosed with Type 2. Initial response to oral medications may be acceptable, reinforcing the misdiagnosis. But over months to years, beta-cell destruction continues and blood sugar worsens despite escalating treatment. The patient eventually requires insulin — not because Type 2 progressed unusually fast, but because the diagnosis was wrong from the start.
The key distinguishing test is islet autoantibody testing — particularly GAD65 antibody. A practical note: because autoantibody tests have imperfect specificity in low-prevalence populations, testing is most meaningful in patients who already have clinical features suggesting autoimmune disease. Confirmatory testing with multiple autoantibody markers improves accuracy. C-peptide is a useful complementary test — low or declining levels support the diagnosis.
- Adult-onset diabetes (typically over age 35) with lean or normal body habitus
- Poor or declining response to oral medications despite apparent adherence
- Rapid progression to insulin requirement within 1–5 years of diagnosis
- Personal or family history of other autoimmune conditions (thyroid disease, celiac, rheumatoid arthritis)
- Extended "honeymoon period" that doesn't resolve as expected
- Fasting C-peptide low relative to stage of disease
MODY — Maturity-Onset Diabetes of the Young
1–5% of all diabetes casesMODY is a group of at least 14 genetically distinct subtypes — each caused by a mutation in a single gene involved in beta-cell function or glucose sensing. Unlike Type 1 (immune-mediated) and Type 2 (multifactorial, polygenic), MODY is monogenic: one gene, one mutation, one dysfunctional pathway. It follows an autosomal dominant inheritance pattern, meaning roughly 50% of first-degree relatives are affected. Onset is typically before age 25, though diagnosis often comes later. Up to 80% of MODY cases are misdiagnosed as Type 1 or Type 2.
The three most common subtypes — MODY2 (GCK gene), MODY3 (HNF1A gene), and MODY1 (HNF4A gene) — account for approximately 95% of all MODY cases and have very different implications. MODY2 results in a higher glucose set point for insulin secretion, causing mild, stable fasting hyperglycemia (typically 100–145 mg/dL) that rarely progresses and generally requires no pharmacological treatment, except during pregnancy. MODY1 and MODY3 cause progressive hyperglycemia with vascular complications similar in severity to Type 1 or Type 2 — but respond exceptionally well to low-dose sulfonylureas, often better than to insulin. Correct diagnosis enables the right drug and allows genetic screening of family members.
- Diabetes diagnosed before age 35, without typical Type 2 risk factors (not obese, physically active)
- Strong multigenerational family history — roughly 50% of first-degree relatives affected
- Negative autoimmune antibodies (distinguishes from Type 1 and LADA)
- Mild, stable fasting hyperglycemia that hasn't worsened over years (suggests MODY2)
- Dramatic response to low-dose sulfonylurea beyond what Type 2 would predict (suggests MODY1 or MODY3)
- Absence of metabolic syndrome features: no obesity, normal blood pressure, normal lipids
Gestational Diabetes Mellitus (GDM)
~6–9% of pregnanciesGestational diabetes is defined as glucose intolerance first identified during pregnancy. The placenta produces hormones that progressively increase insulin resistance as pregnancy advances — a normal physiological adaptation that ensures adequate glucose delivery to the growing fetus. In women whose beta-cell reserve cannot compensate for that resistance, blood sugar rises and gestational diabetes develops, typically in the second or third trimester.
GDM carries real risks for both mother and baby: larger-than-average birth weight (macrosomia), increased cesarean delivery rates, neonatal hypoglycemia, and — over the longer term — a significantly elevated risk of the mother developing Type 2 diabetes. A Lancet systematic review and meta-analysis found a roughly 50% lifetime risk of Type 2 in women who had GDM, making postpartum follow-up important and frequently neglected.
- Repeat glucose tolerance testing 6–12 weeks postpartum — GDM can unmask pre-existing glucose dysregulation
- Ongoing screening every 1–3 years thereafter given high lifetime Type 2 risk
- Lifestyle intervention during and after pregnancy reduces conversion to Type 2
Type 3c Diabetes (Pancreatogenic Diabetes)
~5–10% of diabetes in Western populationsType 3c diabetes results from structural damage to the pancreas — not through autoimmune attack, but through physical destruction or dysfunction. Chronic pancreatitis is the most common cause, accounting for nearly 80% of Type 3c cases, and up to 50% of patients with chronic pancreatitis develop diabetes within 10 years of diagnosis. Other causes include pancreatic cancer, cystic fibrosis, hemochromatosis, and pancreatectomy. Acute pancreatitis is also a significant contributor — its higher population frequency makes it a likely leading cause of pancreatogenic diabetes overall.
The pathophysiology of Type 3c differs from both Type 1 and Type 2 in an important way: all islet cell types are affected, resulting in deficiency not only of insulin but also of glucagon and pancreatic polypeptide. This creates brittle, rapidly fluctuating glucose patterns that are harder to manage. Hepatic insulin resistance and a reduced incretin effect compound the problem. Despite accounting for 5–10% of diabetes cases, more than 97% of Type 3c cases are misclassified as Type 2 in clinical records. This matters for treatment: incretin-based therapies — GLP-1 receptor agonists and DPP-4 inhibitors — should be used with caution in patients with significant pancreatic disease history. It's worth noting that large cardiovascular outcomes trials have not confirmed a meaningful increase in pancreatitis rates in the general diabetes population (as discussed in our GLP-1 Receptor Agonist Series and in Post 3 — Treatment), but in patients with already-damaged pancreatic tissue, the calculus is different and warrants individualized judgment. Pancreatic enzyme replacement therapy (PERT) is often needed alongside glucose management.
- Known history of pancreatic disease — pancreatitis, pancreatic cancer, cystic fibrosis, hemochromatosis
- Prior pancreatic surgery, even partial
- Diabetes onset following an episode of acute or chronic pancreatitis
- Exocrine pancreatic insufficiency symptoms: fatty, greasy stools; weight loss; malabsorption
- Highly variable glucose levels, frequent hypoglycemia, or unusual insulin sensitivity
- Low fecal elastase (a marker of pancreatic exocrine function)
A Note on Pre-Diabetes
Pre-diabetes is not a type of diabetes — it's a transitional state in which blood glucose is above normal but below the threshold for a diabetes diagnosis. Specifically: a fasting glucose of 100–125 mg/dL, an A1c of 5.7–6.4%, or a 2-hour glucose of 140–199 mg/dL on a glucose tolerance test. It represents early impairment of the glucose-insulin system — most often insulin resistance — but with beta cells still compensating adequately. That compensatory capacity is what distinguishes it from Type 2.
Pre-diabetes carries its own cardiovascular risk, independent of whether it progresses to frank diabetes. And as noted in Post 1, it is not inevitable: the Diabetes Prevention Program showed that lifestyle intervention — 150 minutes of moderate activity per week and 5–7% weight loss — reduced progression to Type 2 by 58% over 3 years. The window for intervention is real, and it closes.
Pre-diabetes is a warning signal, not a verdict. If you make real changes to how you eat and move, there's a genuine chance you never develop diabetes at all — and the data backs that up. In clinical practice, I don't generally recommend starting metformin for pre-diabetes, even though it's sometimes suggested. My concern is that metformin can mask progression to true diabetes by modestly lowering blood sugar without addressing the underlying disease. If someone does cross into diabetes while on metformin, we lose the clarity to know when that transition happened — and more importantly, we now have access to medications that are meaningfully superior to metformin for long-term health outcomes: GLP-1 receptor agonists and SGLT2 inhibitors, which reduce cardiovascular and kidney risk in ways metformin simply doesn't (covered in detail in Post 3 — Treatment). I'd rather know when we've transitioned to diabetes so we can start great therapy, rather than keeping patients on metformin — which lacks many of those additional benefits.
How Diagnosis Is Made
Diabetes is diagnosed using one of four criteria, each needing to be confirmed on a repeat test unless symptoms are unambiguous:
Any one of the following, confirmed on repeat testing:
- Fasting plasma glucose ≥ 126 mg/dL — no caloric intake for at least 8 hours
- 2-hour plasma glucose ≥ 200 mg/dL on a 75g oral glucose tolerance test (OGTT)
- A1c ≥ 6.5% — reflects average blood glucose over roughly 3 months
- Random plasma glucose ≥ 200 mg/dL with classic symptoms (excessive thirst, frequent urination, unexplained weight loss)
Meeting the glucose threshold is only the first step. Getting the type right requires additional workup. In adults who are lean, young, or have atypical presentations — or who respond poorly to standard Type 2 therapy — testing for autoimmune markers (GAD65 antibody, C-peptide) and considering genetic testing for MODY is warranted. The 2026 ADA Standards emphasize that diagnostic accuracy for LADA improves with higher-specificity antibody tests and confirmation with multiple autoantibody markers.